National Research Corporation (NRC): VRIO Analysis [Mar-2026 Updated]

Unlock the secrets to National Research Corporation (NRC)'s enduring success! This VRIO Analysis cuts straight to the core, revealing precisely how the firm's Value, Rarity, Inimitability, and Organization translate into sustainable competitive advantage, summarized by the key findings in &O4&. Dive in now to discover the tangible resources driving their market position and what it means for their future performance.

National Research Corporation (NRC) - VRIO Analysis: 1. Subscription Business Model

You’re looking at National Research Corporation (NRC) and seeing the undeniable strength of its recurring revenue engine, which is the key to its valuation, even with some near-term margin noise. The direct takeaway is that the subscription model is the durable competitive advantage, evidenced by the $\text{Q3 2025}$ figures.

Here’s a quick look at the $\text{Q3 2025}$ scorecard that underpins this model:

Value: Predictable Financial Backbone

The subscription model provides highly predictable, recurring revenue, which is the backbone of financial stability. This is clearly evidenced by the \$141.7 million Total Recurring Contract Value (TRCV) as of $\text{Q3 2025}$. This forward-looking metric shows clients are committed to multi-year data services, which is exactly what you want to see in a service provider.

Rarity: Moderately Rare in Healthcare Analytics

This structure is moderately rare; many competitors in the healthcare intelligence space still rely on project-based work or lower-retention software contracts. NRC Health’s deep embedding within a hospital system’s annual measurement and improvement cycles makes its recurring revenue base less common than transactional competitors.

Imitability: Difficult Due to High Switching Costs

It’s difficult for a competitor to copy this moat quickly. Switching costs for healthcare systems already embedded in NRC Health’s annual measurement cycles are high, especially when the CEO, Trent Green, noted a meaningful improvement in customer retention and the best quarterly customer expansion activity in six years. If onboarding takes 14+ days, churn risk rises, but here, the stickiness is structural.

Organization: Strong Alignment with Model Growth

The organization is clearly driving sequential TRCV growth for four straight quarters. Furthermore, management signaled confidence by increasing the quarterly cash dividend by 33% to \$0.16 per share, which is a strong organizational commitment to shareholder returns based on the recurring cash flow.

• Opportunity: Strong $\text{TRCV}$ growth suggests future revenue acceleration.
• Risk: Certain marketing expenses may return in $\text{Q4 2025}$, pressuring near-term margins.

Competitive Advantage: Sustained

The recurring nature of the revenue, combined with high switching costs in the critical patient experience measurement space, creates a durable moat against transactional competitors. This is a sustained competitive advantage, provided they keep innovating their AI-enabled solutions.

Finance: draft $\text{13}$-week cash view by Friday.

National Research Corporation (NRC) - VRIO Analysis: 2. Proprietary Human Understanding® Methodology

The unique, empathic framework differentiates insights, helping clients build trust, which is the core mandate for healthcare leaders. NRC Health received the esteemed 2025 Best in KLAS Award for Healthcare Experience Management for the second time in three years.

Rare; a deeply ingrained, trademarked approach built over 40+ years of industry leadership.

Very difficult; requires institutional knowledge and cultural adoption, not just purchasing a dataset. The methodology is based on rigorous scientific development involving 5 focus groups and analysis of 115 existing questions across over 900 surveys.

Excellent; central to brand and product narrative, validated by the 2025 Best in KLAS Award. The methodology is supported by the Market Insights study measuring over 300,000 people annually and Experience Touchpoints registering over 25 million responses in the past year (as of 2023 data).

Behavioral signs of Human Understanding boil down to three themes:

• Connect with me
• Listen to me
• Partner with me

Sustained; this intellectual property is a core differentiator in experience management, evidenced by the following quantifiable impacts:

National Research Corporation (NRC) - VRIO Analysis: 3. Healthcare Experience Data Assets

Massive, longitudinal datasets on patient, employee, and consumer experience across thousands of organizations fuel their analytics and AI capabilities.

Rare; the sheer volume and depth of historical, proprietary healthcare experience data are unmatched by newer entrants.

Very difficult; competitors would need decades of consistent data collection to match this scale.

Well-organized; the platform integrates this data to deliver actionable insights, leading to a strong 31% Adjusted EBITDA margin in Q3 2025.

Sustained; data scale creates a network effect for better predictive models.

The scale of data collection supports the VRIO framework elements:

• Data Scope: Largest online healthcare-consumer perception study in the U.S.
• Data Depth: Experience surveys gathered most data within 48 hours of a clinical encounter.
• Financial Output: TRCV grew 8% year-over-year to $141.7 million in Q3 2025.

National Research Corporation (NRC) - VRIO Analysis: 4. Industry Recognition and Brand Trust

The industry recognition component of NRC's intangible assets is assessed based on its consistent performance validated by third-party industry benchmarks.

VRIO Assessment Components:

Supporting Statistical and Financial Data:

• NRC Health received the 2025 Best in KLAS Award for Healthcare Experience Management.
• The company has been in operation for more than 40 years.
• The 2025 award marks the second time in three years NRC Health has received this specific recognition.
• NRC Health’s Market Insights study measures insights from more than 310,000 individuals annually for its Consumer Loyalty Awards.
• The 2025 Consumer Loyalty Awards selection is based on Net Promoter Scores (NPS) from April 1, 2024, through March 31, 2025.
• National Research Corporation (NRC) had annual revenue of $143.06M in the year 2024.
• The trailing twelve months (TTM) revenue as of the quarter ending September 30, 2025, was $139.10M.
• The company's Market Cap was reported at $359.57M, with 368 employees.

National Research Corporation (NRC) - VRIO Analysis: 5. Extensive Client Footprint and Market Reach

Value: Serving a significant base of healthcare organizations across the US and Canada provides a massive base for cross-selling and market intelligence gathering. The Market Insights database gathers data from more than 310,000 respondents reporting from 300 different markets.

Rarity: Moderately rare; penetration across acute and long-term care sectors is significant, evidenced by the recurring contract value metrics.

Imitability: Costly and time-consuming; establishing relationships with a large number of health systems requires substantial time investment.

Organization: Organized; evidenced by strong forward-looking sales momentum and recent financial performance metrics.

The organization's subscription core shows resilience, as reflected in the Total Recurring Contract Value (TRCV) growth:

• TRCV as of Q3 2025 reached $141.7 million.
• TRCV represented an 8% year-over-year increase as of Q3 2025.
• The 8% TRCV growth in Q3 2025 was the strongest since 2020.

The following table details key financial figures for the quarter ending September 30, 2025 (Q3 2025):

The company has also signaled confidence through capital allocation decisions:

• The dividend was increased by 33%.

Competitive Advantage: Sustained; the established installed base and recurring revenue base act as a barrier to entry for new competitors, supported by the $141.7 million TRCV.

National Research Corporation (NRC) - VRIO Analysis: 6. Total Recurring Contract Value (TRCV) Momentum

Value: Total Recurring Contract Value (TRCV) was $141.7 million as of Q3 2025, representing a 40% sequential growth in cash flow from operations to $13.8 million for the quarter.

Rarity: Q3 2025 TRCV increased 8% year-over-year to $141.7 million, marking the strongest growth since 2020.

Imitability: TRCV losses and down sells were reduced by nearly 50%. The net retention rate achieved its highest level since 2020. Customer expansion activity was reported as the best in six years.

Organization: Management specifically highlighted drivers for TRCV momentum:

• Reduced TRCV losses and downsells by nearly 50%.
• Achieved the highest net retention rate since 2020.
• Reported the best quarterly customer expansion activity in six years.
• Announced a 33% increase in the quarterly cash dividend to $0.16 per share.

Competitive Advantage: The current momentum is evidenced by four consecutive quarters of sequential TRCV growth.

Key Financial Metrics for Context (Q3 2025):

National Research Corporation (NRC) - VRIO Analysis: 7. Integrated Solutions Portfolio

Value: The ability to sell across Patient, Employee, and Market Experience allows for larger contract sizes and deeper integration into client operations.

The integrated portfolio drives significant forward-looking revenue, evidenced by the Total Recurring Contract Value (TRCV) reaching $141.7 million as of Q3 2025, representing an 8% year-over-year increase. This metric reflects the stickiness and increased scope of bundled contracts. The value proposition is underscored by the estimated lifetime value of each customer/patient being $1.2 million for health systems.

Rarity: Moderately rare; many competitors focus on only one or two experience dimensions.

NRC Health's comprehensive platform covering multiple experience dimensions is recognized by industry benchmarks:

• Received the 2025 Best in KLAS Award for Healthcare Experience Management.
• Received the 2023 Best in KLAS Award for Patient Experience Improvement.

Imitability: Moderately difficult; requires successful past acquisitions or significant internal R&D investment to bundle effectively.

The bundling capability is supported by strategic investments, such as the acquisition of Patient Wisdom in 2021, which enhanced the MyStory solution for capturing patient-generated contextual data integrated into the EHR. Furthermore, the company has integrated solutions like Nobl's rounding capabilities.

Organization: Developing; the focus on modernizing the technology platform suggests ongoing efforts to better integrate these modules.

Organizational structure has been recently adapted to capitalize on growth runways:

• In January 2024, new leadership roles were added, including Chief Revenue Officer, Chief Customer Officer, Chief Product Technology Officer, and Chief Corporate Development Officer.
• The platform is being modernized with an AI-enabled product suite, including the Huey™ AI engine.

Competitive Advantage: Sustained; integration creates stickiness and makes the total solution more valuable than component parts.

The integrated approach yields measurable superior outcomes, creating a high barrier to substitution. Patients experiencing human-centered care are 12x more likely to be promoters, resulting in a collective Net Promoter Score (NPS) of 81, significantly higher than the 5 NPS delivered by those not experiencing that level of care.

National Research Corporation (NRC) - VRIO Analysis: 8. Strong Cash Flow Generation

Value: The ability to convert revenue to cash funds strategic flexibility, investment in R&D (like AI initiatives), and shareholder returns. Q3 2025 Cash Flow from Operations was \$13.8 million.

Rarity: Moderately rare; Q2 2025 showed margin compression, but Q3 2025 cash flow surged 46% year-over-year, indicating strong working capital management.

Imitability: Difficult; it relies on profitability and efficient collections, which are hard to force quickly.

Organization: Improving; the significant cash flow jump suggests the new leadership is focusing on operational discipline.

Competitive Advantage: Temporary; cash flow can be volatile, but the recent surge shows strong organizational focus.

The operational efficiency driving cash flow generation is evidenced by key financial metrics across recent quarters:

The organizational focus on operational discipline and capital allocation is further supported by specific Q3 2025 achievements:

• Total Recurring Contract Value (TRCV) increased 8% year-over-year to \$141.7 million.
• TRCV losses/downsells were reduced nearly 50%.
• The quarterly dividend was increased 33% to \$0.16 per share.
• The company repurchased 618,264 shares at an average price of \$14.99 per share.
• Adjusted EBITDA was \$10.9 million, an 11% year-over-year increase.

National Research Corporation (NRC) - VRIO Analysis: 9. Commitment to Shareholder Returns

Value: An aggressive capital return program, including a 33% dividend increase to \$0.16 per share declared in October 2025, signals management confidence in future earnings. The company returned a total of \$28.1 million to shareholders through dividends and stock repurchases during 2025.

Rarity: Moderately rare; funding capital returns via share repurchases and dividend increases while maintaining modest leverage and positive cash flow generation is a bold, though risky, move.

Imitability: Difficult; requires board approval and the financial capacity to execute the buybacks and dividends, supported by Q3 2025 Adjusted EBITDA of \$10.9 million.

Organization: Clear; the company has a defined policy for returning value, which attracts a certain class of investor, as evidenced by the forward annual dividend of \$0.64 per share and a forward payout ratio of 73.24%.

Competitive Advantage: Temporary; this is a financial policy choice, not an operational advantage, and can be reversed if performance falters, as seen by the 0 successive years of dividend increases as of March 2025.

Finance: Draft 13-week cash view by Friday.

Key Capital Allocation Metrics:

• Q3 2025 Quarterly Cash Dividend Declared: \$0.16 per share.
• Previous Quarterly Dividend: \$0.12 per share.
• Q3 2025 Share Repurchase Volume: 618,264 shares.
• Q3 2025 Share Repurchase Value: \$9.3 million.
• Q2 2025 Share Repurchase Volume: 382,000 shares.
• April 2025 Closed Buyback Volume: 1,000,000 shares.
• April 2025 Closed Buyback Value: \$14.98 million.
• Q4 2024 Dividend Payment: Approximately \$2.8 million.

Selected Financial Data Supporting Capital Returns: